KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Shares Issued (2016 - 2025)

Jazz Pharmaceuticals has reported Shares Issued over the past 16 years, most recently at $85.2 million for Q4 2025.

  • Quarterly results put Shares Issued at $85.2 million for Q4 2025, up 826.34% from a year ago — trailing twelve months through Dec 2025 was $107.9 million (up 422.41% YoY), and the annual figure for FY2025 was $107.9 million, up 422.41%.
  • Shares Issued for Q4 2025 was $85.2 million at Jazz Pharmaceuticals, up from $733000.0 in the prior quarter.
  • Over the last five years, Shares Issued for JAZZ hit a ceiling of $85.2 million in Q4 2025 and a floor of $17000.0 in Q3 2024.
  • Median Shares Issued over the past 5 years was $13.1 million (2021), compared with a mean of $20.4 million.
  • Biggest five-year swings in Shares Issued: tumbled 99.69% in 2024 and later surged 4211.76% in 2025.
  • Jazz Pharmaceuticals' Shares Issued stood at $18.2 million in 2021, then surged by 66.15% to $30.2 million in 2022, then tumbled by 70.64% to $8.9 million in 2023, then rose by 3.87% to $9.2 million in 2024, then skyrocketed by 826.34% to $85.2 million in 2025.
  • The last three reported values for Shares Issued were $85.2 million (Q4 2025), $733000.0 (Q3 2025), and $10.5 million (Q2 2025) per Business Quant data.